Search Results

Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Atypical Structure

Explore structure-based design of purinergic GPCR modulators with NIH scientist Kenneth A. . < Back Structure-Based Design of Modulators of Purinergic GPCRs March 12, 2026 at 2:00:00 PM 🔒 Watch This session examines how structure-based approaches have guided the discovery of selective ligands targeting A medicinal chemist specializing in the structure and pharmacology of G protein-coupled receptors and His research focuses on developing computational pipelines for rational ligand design targeting therapeutically

About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Structure-based

Committee Sponsors GPCR Retreat Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure Recently, his team has applied cryo-EM to elucidation of the structure and dynamics of GPCRs. Prof.

optimize the design and engineering of more efficacious therapeutics. perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

His main research group centers on the function, structure, and regulation of G protein-coupled receptors Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Kobilka’s lab contributing to the elucidation of high-resolution structures of various GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr.

An expert in GPCR biology, Fiona published the first description of the cloning and structural requirements As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery company, Fiona and her team made considerable breakthroughs in the field of GPCR stabilization and structure-based

daLUXendin Family Fluorescent dual agonists for both GLP-1R and GIPR (daLUXendin544+ and daLUXendin660+), structurally His work carries direct translational relevance to diabetes and obesity therapeutics. It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured

Her work involves the pharmacological and structural characterisation of novel putative antipsychotic molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

created by scientists, for scientists—bringing the global GPCR community together to advance biology and therapeutics Explore 200+ expert talks that bring GPCR discoveries to life From structural biology to therapeutics players in GPCR pharmacology and learn how agonists and antagonists shape efficacy, signaling, and therapeutic orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.

The Tiberi Lab pursues the study of the molecular, structural, pharmacological and signaling features We hope our research will aid in the development of new therapeutic interventions for the alleviation

Introduction Drug discovery pipelines increasingly depend on screening platforms designed to identify therapeutically the cell surface and within the nucleus, providing insight into how receptor signaling networks are structured

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic How an integrated training and lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic

. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic Pharmacology 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Structural PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics discovery, he later co-founded Superluminal Medicines, a company using machine learning to explore GPCR structure-function

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics expertise and provides you with product solutions including cell-based assays for basic research through therapeutic Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Explore GLP-1 Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics These GPCRs are excellent for use in functional, structural, or identification assays.

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes 📌 Measuring Bias: A Quantitative Approach 🔹 The operational model provides a structured way to measure

Nicola J Smith is an expert in molecular pharmacology with a track record in exploring GPCR structure-function orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

He earned his Ph.D. at the Massachusetts Institute of Technology, where he studied MHC class II structure-function record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications These webinars are ideal for: • GPCR pharmacologists • Medicinal chemists working on receptor targets • Structural Calcium and signaling assays • Drug–receptor kinetics • Translational pharmacology strategies • GPCR structure–function

Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Division of Molecular Therapeutics, New York State without coming out of the GAIN domain or by being partially exposed, however the recent TA-bound 7TM structures Axel Brunger’s lab at Stanford University to study the structure and function of cell-adhesion proteins Gregory Tall and our research primarily focuses on the structural and biochemical characterization of

During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Operational Discipline I instill structure and consistency across every phase of your discovery process Yamina brings the clarity, rigor, and structured decision-making that keeps programs on track. Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed Her input helped us structure the screening funnel, define clear go/no-go criteria, and integrate ADME

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics the relocation of some university labs to facilitate collaboration and overcome the siloed department structure Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization.

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics the relocation of some university labs to facilitate collaboration and overcome the siloed department structure Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization.